The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma : A Nordic Lymphoma Group study
(2017) In British Journal of Haematology 178(5). p.739-746- Abstract
Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALK-). We have analysed the outcome and risk factors for survival in a population-based bi-national cohort of patients with systemic ALK+ ALCL. A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0·4% of all lymphomas. The median age of the cohort was 40 years (range 18-85). The 5-year overall survival and progression-free survival (PFS) was 78% and 64%, respectively. Age was strongly associated with outcome, and only bone marrow (BM)... (More)
Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALK-). We have analysed the outcome and risk factors for survival in a population-based bi-national cohort of patients with systemic ALK+ ALCL. A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0·4% of all lymphomas. The median age of the cohort was 40 years (range 18-85). The 5-year overall survival and progression-free survival (PFS) was 78% and 64%, respectively. Age was strongly associated with outcome, and only bone marrow (BM) involvement was independently associated with poorer PFS in multivariate analysis (Hazard Ratio [HR] = 8·57, P < 0·001). Age stratification of the patients demonstrated an association between treatment with CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) and improved overall survival for patients aged 41-65 years, even when adjusted for risk factors (HR = 0·38, P = 0·047). Our results suggest that the addition of etoposide to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) in the treatment for ALK+ ALCL seems reasonable in this age group.
(Less)
- author
- Cederleuf, Henrik LU ; Bjerregård Pedersen, Martin ; Jerkeman, Mats LU ; Relander, Thomas LU ; d'Amore, Francesco and Ellin, Fredrik LU
- organization
- publishing date
- 2017
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Anaplastic large cell lymphoma, Bone marrow involvement, Etoposide, Peripheral T-cell lymphoma, Population-based
- in
- British Journal of Haematology
- volume
- 178
- issue
- 5
- pages
- 739 - 746
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:28485010
- wos:000407904100011
- scopus:85019077258
- ISSN
- 0007-1048
- DOI
- 10.1111/bjh.14740
- language
- English
- LU publication?
- yes
- id
- 5c642817-c155-46b6-a54f-2ea367b37984
- date added to LUP
- 2017-06-01 13:09:18
- date last changed
- 2025-01-07 14:33:43
@article{5c642817-c155-46b6-a54f-2ea367b37984, abstract = {{<p>Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALK-). We have analysed the outcome and risk factors for survival in a population-based bi-national cohort of patients with systemic ALK+ ALCL. A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0·4% of all lymphomas. The median age of the cohort was 40 years (range 18-85). The 5-year overall survival and progression-free survival (PFS) was 78% and 64%, respectively. Age was strongly associated with outcome, and only bone marrow (BM) involvement was independently associated with poorer PFS in multivariate analysis (Hazard Ratio [HR] = 8·57, P < 0·001). Age stratification of the patients demonstrated an association between treatment with CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) and improved overall survival for patients aged 41-65 years, even when adjusted for risk factors (HR = 0·38, P = 0·047). Our results suggest that the addition of etoposide to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) in the treatment for ALK+ ALCL seems reasonable in this age group.</p>}}, author = {{Cederleuf, Henrik and Bjerregård Pedersen, Martin and Jerkeman, Mats and Relander, Thomas and d'Amore, Francesco and Ellin, Fredrik}}, issn = {{0007-1048}}, keywords = {{Anaplastic large cell lymphoma; Bone marrow involvement; Etoposide; Peripheral T-cell lymphoma; Population-based}}, language = {{eng}}, number = {{5}}, pages = {{739--746}}, publisher = {{Wiley-Blackwell}}, series = {{British Journal of Haematology}}, title = {{The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma : A Nordic Lymphoma Group study}}, url = {{http://dx.doi.org/10.1111/bjh.14740}}, doi = {{10.1111/bjh.14740}}, volume = {{178}}, year = {{2017}}, }